Newsroom | 49465 results

DUBLIN--(BUSINESS WIRE)--The "Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products Training Course (Apr 23rd - Apr 24th, 2026)" training has been added to ResearchAndMarkets.com's offering. The regulatory requirements for Biological drug products are complex, and pharmaceutical companies are continuously under pressure to ensure regulatory compliance from drug discovery to post-marketing surveillance. Information regarding chemistry, manufacturing, and...

HOUSTON--(BUSINESS WIRE)--EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the next and final stage of its pivotal multicenter trial, the PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine). The PARADIGM Trial is an Investigational Device Exemption (IDE) study evaluating EndoQuest’s Endoluminal Surgical (ELS) System fo...

KITCHENER, Ontario--(BUSINESS WIRE)--Nicoya Life Sciences, Inc., a leading provider of advanced biophysical characterization tools for biologics discovery and development, today announced the launch of Revo™, a label-free binding kinetics platform designed to make gold-standard surface plasmon resonance (SPR) data more accessible to a broader range of researchers. By combining the trusted precision of SPR with the simplicity and usability researchers expect from modern benchtop systems, Revo en...

NEWARK, Del.--(BUSINESS WIRE)--QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its cli...

ZURICH & PHILADELPHIA & COPENHAGEN, Denmark--(BUSINESS WIRE)--InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™...

INCHEON, Corea--(BUSINESS WIRE)--Samsung Epis Holdings (KRX: 0126Z0) ha presentato oggi i progressi e gli aggiornamenti aziendali in occasione della 44esima edizione della J.P. Morgan Healthcare Conference. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido....

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss®, currently approved for the treatment of moderate-to-severe atopic dermatitis) in patients with nummular eczema. This study will be initiated in the first half of 2026 and is aligned with Almirall’s ambition of leadership in medical dermatology and is part of the ong...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference....

EVANSTON, Ill.--(BUSINESS WIRE)--Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced the appointment of Venkat R. Krishnamurthy, Ph.D., as Chief Scientific Officer. Dr. Krishnamurthy is an accomplished scientific and executive leader with more than 15 years of experience developing RNA therapeutics, bringing deep expertise in oligonucleotide chemistry, drug delivery, and advancing genetic medicine programs from discovery through c...

MORRISVILLE, Caroline du Nord--(BUSINESS WIRE)--WEP Clinical (WEP), une organisation de recherche sous contrat (ontract research organization, CRO) à services complets, vient d’annoncer l’acquisition de Siron Clinical (Siron), une CRO européenne basée aux Pays-Bas, spécialisée dans les opérations cliniques flexibles et de haute qualité pour les entreprises de biotechnologie. Cette acquisition permet à WEP d’élargir sa présence mondiale et de renforcer sa capacité à fournir des solutions complèt...